These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 37801604)

  • 61. Expanded polyglutamine domain possesses nuclear export activity which modulates subcellular localization and toxicity of polyQ disease protein via exportin-1.
    Chan WM; Tsoi H; Wu CC; Wong CH; Cheng TC; Li HY; Lau KF; Shaw PC; Perrimon N; Chan HY
    Hum Mol Genet; 2011 May; 20(9):1738-50. PubMed ID: 21300695
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes.
    Casasnovas RO; Follows G; Zijlstra JM; Vermaat JSP; Kalakonda N; Choquet S; Neste EVD; Hill B; Thieblemont C; Cavallo F; la Cruz F; Kuruvilla J; Hamad N; Jaeger U; Caimi PF; Gurion R; Warzocha K; Bakhshi S; Sancho JM; Schuster M; Egyed M; Offner F; Vassilakopoulos TP; Samal P; Ku M; Ma X; Chamoun K; Shah J; Canales M; Maerevoet M; Shacham S; Kauffman MG; Goy A
    Clin Lymphoma Myeloma Leuk; 2022 Jan; 22(1):24-33. PubMed ID: 34493477
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in
    Zhang W; Ly C; Ishizawa J; Mu H; Ruvolo V; Shacham S; Daver N; Andreeff M
    Haematologica; 2018 Oct; 103(10):1642-1653. PubMed ID: 29773601
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.
    Vercruysse T; De Bie J; Neggers JE; Jacquemyn M; Vanstreels E; Schmid-Burgk JL; Hornung V; Baloglu E; Landesman Y; Senapedis W; Shacham S; Dagklis A; Cools J; Daelemans D
    Clin Cancer Res; 2017 May; 23(10):2528-2541. PubMed ID: 27780859
    [No Abstract]   [Full Text] [Related]  

  • 65. Chemoproteomic Profiling of Covalent XPO1 Inhibitors to Assess Target Engagement and Selectivity.
    Martin JG; Ward JA; Feyertag F; Zhang L; Couvertier S; Guckian K; Huber KVM; Johnson DS
    Chembiochem; 2021 Jun; 22(12):2116-2123. PubMed ID: 33887086
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [The Latest Research Progress of Selinexor in the Treatment of Non-Hodgkin Lymphoma --Review].
    Tang XY; Wang Y; Xu RR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):292-296. PubMed ID: 36765514
    [TBL] [Abstract][Full Text] [Related]  

  • 67. XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB.
    Ming M; Wu W; Xie B; Sukhanova M; Wang W; Kadri S; Sharma S; Lee J; Shacham S; Landesman Y; Maltsev N; Lu P; Wang YL
    Mol Cancer Ther; 2018 Dec; 17(12):2564-2574. PubMed ID: 30510142
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition.
    Jiménez I; Carabia J; Bobillo S; Palacio C; Abrisqueta P; Pagès C; Nieto JC; Castellví J; Martínez-Ricarte F; Escoda L; Perla C; Céspedes Torrez DH; Boix J; Purroy N; Puigdefàbregas L; Seoane J; Bosch F; Crespo M
    J Neurooncol; 2020 Aug; 149(1):13-25. PubMed ID: 32691208
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing.
    Neggers JE; Vercruysse T; Jacquemyn M; Vanstreels E; Baloglu E; Shacham S; Crochiere M; Landesman Y; Daelemans D
    Chem Biol; 2015 Jan; 22(1):107-16. PubMed ID: 25579209
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines.
    Breit MN; Kisseberth WC; Bear MD; Landesman Y; Kashyap T; McCauley D; Kauffman MG; Shacham S; London CA
    BMC Vet Res; 2014 Jul; 10():160. PubMed ID: 25022346
    [TBL] [Abstract][Full Text] [Related]  

  • 71. NRF2 activators inhibit influenza A virus replication by interfering with nucleo-cytoplasmic export of viral RNPs in an NRF2-independent manner.
    Waqas FH; Shehata M; Elgaher WAM; Lacour A; Kurmasheva N; Begnini F; Kiib AE; Dahlmann J; Chen C; Pavlou A; Poulsen TB; Merkert S; Martin U; Olmer R; Olagnier D; Hirsch AKH; Pleschka S; Pessler F
    PLoS Pathog; 2023 Jul; 19(7):e1011506. PubMed ID: 37459366
    [TBL] [Abstract][Full Text] [Related]  

  • 72. NEDD4 protects vascular endothelial cells against Angiotensin II-induced cell death via enhancement of XPO1-mediated nuclear export.
    Xu J; Sheng Z; Li F; Wang S; Yuan Y; Wang M; Yu Z
    Exp Cell Res; 2019 Oct; 383(1):111505. PubMed ID: 31326389
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Association of XPO1 Overexpression with NF-κB and Ki67 in Colorectal Cancer.
    Aladhraei M; Kassem Al-Thobhani A; Poungvarin N; Suwannalert P
    Asian Pac J Cancer Prev; 2019 Dec; 20(12):3747-3754. PubMed ID: 31870117
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Upregulation of let-7f-2-3p by long noncoding RNA NEAT1 inhibits XPO1-mediated HAX-1 nuclear export in both in vitro and in vivo rodent models of doxorubicin-induced cardiotoxicity.
    Liu Y; Duan C; Liu W; Chen X; Wang Y; Liu X; Yue J; Yang J; Zhou X
    Arch Toxicol; 2019 Nov; 93(11):3261-3276. PubMed ID: 31570982
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
    Vogl DT; Dingli D; Cornell RF; Huff CA; Jagannath S; Bhutani D; Zonder J; Baz R; Nooka A; Richter J; Cole C; Vij R; Jakubowiak A; Abonour R; Schiller G; Parker TL; Costa LJ; Kaminetzky D; Hoffman JE; Yee AJ; Chari A; Siegel D; Fonseca R; Van Wier S; Ahmann G; Lopez I; Kauffman M; Shacham S; Saint-Martin JR; Picklesimer CD; Choe-Juliak C; Stewart AK
    J Clin Oncol; 2018 Mar; 36(9):859-866. PubMed ID: 29381435
    [TBL] [Abstract][Full Text] [Related]  

  • 76. XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal Cancer.
    Ferreiro-Neira I; Torres NE; Liesenfeld LF; Chan CH; Penson T; Landesman Y; Senapedis W; Shacham S; Hong TS; Cusack JC
    Clin Cancer Res; 2016 Apr; 22(7):1663-73. PubMed ID: 26603256
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Electrophile Determines Cellular Phenotypes among XPO1-Targeting Small Molecules.
    Chen YF; Shen Y; Yan DF; Ghazala M; Scemama de Gialluly MA; Srinivasan R; Farrar AN; Friedrich RM; Adams DJ
    J Med Chem; 2024 Jul; 67(14):12033-12054. PubMed ID: 39005064
    [TBL] [Abstract][Full Text] [Related]  

  • 78. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
    Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
    Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth.
    Wettersten HI; Landesman Y; Friedlander S; Shacham S; Kauffman M; Weiss RH
    PLoS One; 2014; 9(12):e113867. PubMed ID: 25461627
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A drug profile on selinexor for the treatment of refractory diffuse large B-cell lymphoma.
    Sylvain C
    Expert Rev Hematol; 2022 Mar; 15(3):195-201. PubMed ID: 35318887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.